Omalizumab (Xolair) is a monoclonal antibody that is recommended as add-on treatment in patients with severe persistent uncontrolled allergic asthma. It is currently prescribed in severe asthmatics sensitized to perennial allergens, which are thought to be responsible for the persistent status of inflamed airways. This is the case for dust mite, which has been associated with severe asthma. However, other allergens can cause perennial allergy–like conditions and therefore—albeit with reduced prevalence—severe asthma.
Different skin prick test sensitization patterns do not influence the response to omalizumab in severe asthma / Sposato, B; Scalese, M; Milanese, M; Masieri, S; Cavaliere, C; Latorre, M; Scichilone, N; Matucci, A; Vultaggio, A; Ricci, A; Cresti, A; Paggiaro, P. L.. - In: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY. - ISSN 1018-9068. - 27:6(2017), pp. 388-391. [10.18176/jiaci.0196]
Different skin prick test sensitization patterns do not influence the response to omalizumab in severe asthma
Masieri, S;Cavaliere, C;Ricci, A;
2017
Abstract
Omalizumab (Xolair) is a monoclonal antibody that is recommended as add-on treatment in patients with severe persistent uncontrolled allergic asthma. It is currently prescribed in severe asthmatics sensitized to perennial allergens, which are thought to be responsible for the persistent status of inflamed airways. This is the case for dust mite, which has been associated with severe asthma. However, other allergens can cause perennial allergy–like conditions and therefore—albeit with reduced prevalence—severe asthma.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sposato_Different_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
451.56 kB
Formato
Adobe PDF
|
451.56 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
